Lorne Gertner

Lorne is a co-founder of GoodCap Pharmaceuticals Inc. His prior experience in drug development includes co-founding Cannasat Therapeutics, which later became Cynapsus Therapeutics which sold to pharmaceutical giant Sunovion Pharmaceuticals Inc. in 2016 for C$841 million. As a pioneer within disruptive industries, he co-founded and is the former chairman of PharmaCan Capital Corporation, now doing business as the publicly traded (TSX) Cronos Group Inc. He is also a co-founder of the Tokyo Smoke brand which is now owned by Canopy Growth after a purchase in 2018.